{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:22Z","timestamp":1786979902594,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CSCO-hengrui Cancer Research Fund","award":["[Y-HR2019-0239] [Y-HR2020QN-0414]"],"award-info":[{"award-number":["[Y-HR2019-0239] [Y-HR2020QN-0414]"]}]},{"name":"CSCO-hengrui Cancer Research Fund","award":["[Y-HR2019-0239] [Y-HR2020QN-0414]"],"award-info":[{"award-number":["[Y-HR2019-0239] [Y-HR2020QN-0414]"]}]},{"name":"the Department of Science and Technology of Guizhou Province","award":["(No. Qiankehe Foundation [2020] 1Y302)"],"award-info":[{"award-number":["(No. Qiankehe Foundation [2020] 1Y302)"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(No. 81960125)"],"award-info":[{"award-number":["(No. 81960125)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["[2022-PUMCH-B-128]"],"award-info":[{"award-number":["[2022-PUMCH-B-128]"]}]},{"name":"CAMS Innovation Fund for Medical Sciences\uff08CIFMS\uff09","award":["[2022-I2M-C&T-A-003] [2021-I2M-1-061] [2021-I2M-1-003]"],"award-info":[{"award-number":["[2022-I2M-C&T-A-003] [2021-I2M-1-061] [2021-I2M-1-003]"]}]},{"name":"CSCO-MSD Cancer Research Fund","award":["[Y-MSDZD2021-0213]"],"award-info":[{"award-number":["[Y-MSDZD2021-0213]"]}]},{"DOI":"10.13039\/501100018538","name":"National Ten-thousand Talent Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018538","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-024-03831-1","type":"journal-article","created":{"date-parts":[[2024,10,2]],"date-time":"2024-10-02T21:01:16Z","timestamp":1727902876000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancer"],"prefix":"10.1007","volume":"73","author":[{"given":"Yang","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengpei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunchao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiashuo","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daobing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"key":"3831_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B et al (2021) Biliary tract cancer. Lancet 397:428\u2013444. https:\/\/doi.org\/10.1016\/S0140-6736(21)00153-7","journal-title":"Lancet"},{"key":"3831_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"3831_CR3","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281. https:\/\/doi.org\/10.1056\/NEJMoa0908721","journal-title":"N Engl J Med"},{"key":"3831_CR4","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","volume":"22","author":"A Lamarca","year":"2021","unstructured":"Lamarca A, Palmer DH, Wasan HS et al (2021) Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22:690\u2013701. https:\/\/doi.org\/10.1016\/S1470-2045(21)00027-9","journal-title":"Lancet Oncol"},{"key":"3831_CR5","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","volume":"22","author":"C Yoo","year":"2021","unstructured":"Yoo C, Kim K-P, Jeong JH et al (2021) Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 22:1560\u20131572. https:\/\/doi.org\/10.1016\/S1470-2045(21)00486-1","journal-title":"Lancet Oncol"},{"key":"3831_CR6","doi-asserted-by":"publisher","first-page":"100335","DOI":"10.1016\/j.ctarc.2021.100335","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G (2021) First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 Trial: \u201cand yet it moves!\u201d Cancer Treat Res Commun 27:100335. https:\/\/doi.org\/10.1016\/j.ctarc.2021.100335","journal-title":"Cancer Treat Res Commun"},{"key":"3831_CR7","doi-asserted-by":"publisher","first-page":"e001240","DOI":"10.1136\/jitc-2020-001240","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, Wu X, Wu H et al (2020) Camrelizumab plus gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer: a single-arm, open-label, phase II trial. J Immunother Cancer 8:e001240. https:\/\/doi.org\/10.1136\/jitc-2020-001240","journal-title":"J Immunother Cancer"},{"key":"3831_CR8","doi-asserted-by":"publisher","first-page":"e000367","DOI":"10.1136\/jitc-2019-000367","volume":"8","author":"K Feng","year":"2020","unstructured":"Feng K, Liu Y, Zhao Y et al (2020) Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study. J Immunother Cancer 8:e000367. https:\/\/doi.org\/10.1136\/jitc-2019-000367","journal-title":"J Immunother Cancer"},{"key":"3831_CR9","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200015","author":"D-Y Oh","year":"2022","unstructured":"Oh D-Y, Ruth He A, Qin S et al (2022) Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid. https:\/\/doi.org\/10.1056\/EVIDoa2200015","journal-title":"NEJM Evid"},{"key":"3831_CR10","doi-asserted-by":"publisher","first-page":"S570","DOI":"10.1016\/j.annonc.2022.07.093","volume":"33","author":"H Li","year":"2022","unstructured":"Li H (2022) A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers. Ann Oncol 33:S570. https:\/\/doi.org\/10.1016\/j.annonc.2022.07.093","journal-title":"Ann Oncol"},{"key":"3831_CR11","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41392-023-01317-7","volume":"8","author":"G-M Shi","year":"2023","unstructured":"Shi G-M, Huang X-Y, Wu D et al (2023) Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study. Signal Transduct Target Ther 8:106. https:\/\/doi.org\/10.1038\/s41392-023-01317-7","journal-title":"Signal Transduct Target Ther"},{"key":"3831_CR12","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1007\/s00262-023-03466-8","volume":"72","author":"C Zhu","year":"2023","unstructured":"Zhu C, Li H, Yang X et al (2023) Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world study. Cancer Immunol Immunother 72:2949\u20132960. https:\/\/doi.org\/10.1007\/s00262-023-03466-8","journal-title":"Cancer Immunol Immunother"},{"key":"3831_CR13","doi-asserted-by":"publisher","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","volume":"14","author":"C Zhu","year":"2023","unstructured":"Zhu C, Xue J, Wang Y et al (2023) Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Front Immunol 14:1109292. https:\/\/doi.org\/10.3389\/fimmu.2023.1109292","journal-title":"Front Immunol"},{"key":"3831_CR14","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/aps.2016.161","volume":"38","author":"J Fu","year":"2017","unstructured":"Fu J, Wang F, Dong L-H et al (2017) Preclinical evaluation of the efficacy, pharmacokinetics and immunogenicity of JS-001, a programmed cell death protein-1 (PD-1) monoclonal antibody. Acta Pharmacol Sin 38:710\u2013718. https:\/\/doi.org\/10.1038\/aps.2016.161","journal-title":"Acta Pharmacol Sin"},{"key":"3831_CR15","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C et al (2023) Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 401:1853\u20131865. https:\/\/doi.org\/10.1016\/S0140-6736(23)00727-4","journal-title":"Lancet"},{"key":"3831_CR16","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jamaoncol.2023.4003","volume":"9","author":"S Qin","year":"2023","unstructured":"Qin S, Kudo M, Meyer T et al (2023) Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3 randomized clinical trial. JAMA Oncol 9:1651\u20131659. https:\/\/doi.org\/10.1001\/jamaoncol.2023.4003","journal-title":"JAMA Oncol"},{"key":"3831_CR17","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1007\/s00262-021-03121-0","volume":"71","author":"B Zuo","year":"2022","unstructured":"Zuo B, Yang X, Yang X et al (2022) A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer. Cancer Immunol Immunother 71:1889\u20131896. https:\/\/doi.org\/10.1007\/s00262-021-03121-0","journal-title":"Cancer Immunol Immunother"},{"key":"3831_CR18","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.cca.2018.06.032","volume":"485","author":"M-J Qiu","year":"2018","unstructured":"Qiu M-J, He X-X, Bi N-R et al (2018) Effects of liver-targeted drugs on expression of immune-related proteins in hepatocellular carcinoma cells. Clin Chim Acta 485:103\u2013105. https:\/\/doi.org\/10.1016\/j.cca.2018.06.032","journal-title":"Clin Chim Acta"},{"key":"3831_CR19","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1007\/s00262-023-03366-x","volume":"72","author":"A Rizzo","year":"2023","unstructured":"Rizzo A, Mollica V, Tateo V et al (2023) Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study. Cancer Immunol Immunother 72:1381\u20131394. https:\/\/doi.org\/10.1007\/s00262-023-03366-x","journal-title":"Cancer Immunol Immunother"},{"key":"3831_CR20","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1007\/s00520-023-08083-w","volume":"31","author":"DC Guven","year":"2023","unstructured":"Guven DC, Erul E, Kaygusuz Y et al (2023) Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer 31:624. https:\/\/doi.org\/10.1007\/s00520-023-08083-w","journal-title":"Support Care Cancer"},{"key":"3831_CR21","doi-asserted-by":"publisher","first-page":"1039121","DOI":"10.3389\/fmolb.2022.1039121","volume":"9","author":"DC Guven","year":"2022","unstructured":"Guven DC, Sahin TK, Erul E et al (2022) The association between albumin levels and survival in patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis. Front Mol Biosci 9:1039121. https:\/\/doi.org\/10.3389\/fmolb.2022.1039121","journal-title":"Front Mol Biosci"},{"key":"3831_CR22","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1186\/s12967-023-04419-6","volume":"21","author":"D Mallardo","year":"2023","unstructured":"Mallardo D, Fordellone M, White A et al (2023) CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy. J Transl Med 21:610. https:\/\/doi.org\/10.1186\/s12967-023-04419-6","journal-title":"J Transl Med"},{"key":"3831_CR23","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S et al (2016) RECIST 1.1\u2014standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer 62:138\u2013145. https:\/\/doi.org\/10.1016\/j.ejca.2016.03.082","journal-title":"Eur J Cancer"},{"key":"3831_CR24","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1016\/j.jtho.2018.05.038","volume":"13","author":"J Quispel-Janssen","year":"2018","unstructured":"Quispel-Janssen J, van der Noort V, de Vries JF et al (2018) Programmed death 1 blockade with nivolumab in patients with recurrent malignant pleural mesothelioma. J Thorac Oncol 13:1569\u20131576. https:\/\/doi.org\/10.1016\/j.jtho.2018.05.038","journal-title":"J Thorac Oncol"},{"key":"3831_CR25","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.21037\/atm-21-4747","volume":"9","author":"Q Zheng","year":"2021","unstructured":"Zheng Q, Wu C, Ye H et al (2021) Analysis of the efficacy and prognostic factors of PD-1 inhibitors in advanced gallbladder cancer. Ann Transl Med 9:1568","journal-title":"Ann Transl Med"},{"key":"3831_CR26","doi-asserted-by":"publisher","first-page":"751391","DOI":"10.3389\/fonc.2021.751391","volume":"11","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Liu X, Wei S et al (2021) Lenvatinib plus PD-1 inhibitors as first-line treatment in patients with unresectable biliary tract cancer: a single-arm, open-label. Phase II Study Front Oncol 11:751391. https:\/\/doi.org\/10.3389\/fonc.2021.751391","journal-title":"Phase II Study Front Oncol"},{"key":"3831_CR27","doi-asserted-by":"publisher","first-page":"S377","DOI":"10.1016\/j.annonc.2021.08.328","volume":"32","author":"N-J Chiang","year":"2021","unstructured":"Chiang N-J, Bai L-Y, Huang C-J et al (2021) 49P A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer. Ann Oncol 32:S377. https:\/\/doi.org\/10.1016\/j.annonc.2021.08.328","journal-title":"Ann Oncol"},{"key":"3831_CR28","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1002\/ijc.34372","volume":"152","author":"S Jin","year":"2023","unstructured":"Jin S, Zhao R, Zhou C et al (2023) Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial. Int J Cancer 152:1648\u20131658. https:\/\/doi.org\/10.1002\/ijc.34372","journal-title":"Int J Cancer"},{"key":"3831_CR29","doi-asserted-by":"publisher","first-page":"4080","DOI":"10.1200\/JCO.2021.39.15_suppl.4080","volume":"39","author":"L Villanueva","year":"2021","unstructured":"Villanueva L, Lwin Z, Chung HCC et al (2021) Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study. JCO 39:4080\u20134080. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.4080","journal-title":"JCO"},{"key":"3831_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi L, Buqu\u00e9 A, Kepp O et al (2015) Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28:690\u2013714. https:\/\/doi.org\/10.1016\/j.ccell.2015.10.012","journal-title":"Cancer Cell"},{"key":"3831_CR31","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/cncr.31872","volume":"125","author":"W Sun","year":"2019","unstructured":"Sun W, Patel A, Normolle D et al (2019) A phase 2 trial of regorafenib as a single agent in patients with chemotherapy-refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer 125:902\u2013909. https:\/\/doi.org\/10.1002\/cncr.31872","journal-title":"Cancer"},{"key":"3831_CR32","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis AA, Patel VG (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US food and drug administration (FDA) approvals of immune checkpoint inhibitors. J Immunother Cancer 7:278","journal-title":"J Immunother Cancer"},{"key":"3831_CR33","doi-asserted-by":"publisher","first-page":"e542","DOI":"10.1016\/S1470-2045(16)30406-5","volume":"17","author":"GT Gibney","year":"2016","unstructured":"Gibney GT, Weiner LM, Atkins MB (2016) Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol 17:e542\u2013e551. https:\/\/doi.org\/10.1016\/S1470-2045(16)30406-5","journal-title":"Lancet Oncol"},{"key":"3831_CR34","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-18-0214","volume":"6","author":"N Tray","year":"2018","unstructured":"Tray N, Weber JS, Adams S (2018) Predictive biomarkers for checkpoint immunotherapy: current status and challenges for clinical application. Cancer Immunol Res 6:1122\u20131128. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0214","journal-title":"Cancer Immunol Res"},{"key":"3831_CR35","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40364-024-00607-8","volume":"12","author":"C Zhu","year":"2024","unstructured":"Zhu C, Wang Y, Zhu R et al (2024) Gut microbiota and metabolites signatures of clinical response in anti-PD-1\/PD-L1 based immunotherapy of biliary tract cancer. Biomark Res 12:56. https:\/\/doi.org\/10.1186\/s40364-024-00607-8","journal-title":"Biomark Res"},{"key":"3831_CR36","doi-asserted-by":"publisher","first-page":"e001042","DOI":"10.1136\/esmoopen-2020-001042","volume":"5","author":"AD Ricci","year":"2020","unstructured":"Ricci AD, Rizzo A, Brandi G (2020) The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora\u2019s box? ESMO Open 5:e001042. https:\/\/doi.org\/10.1136\/esmoopen-2020-001042","journal-title":"ESMO Open"},{"key":"3831_CR37","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/cancers16101835","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Rizzo A, Aksoy S, Guven DC (2024) Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: a systematic review and meta-analysis. Cancers 16:1835. https:\/\/doi.org\/10.3390\/cancers16101835","journal-title":"Cancers"},{"key":"3831_CR38","doi-asserted-by":"publisher","first-page":"414","DOI":"10.21037\/hbsn-20-338","volume":"9","author":"J Lin","year":"2020","unstructured":"Lin J, Yang X, Long J et al (2020) Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma. Hepatobiliary Surg Nutr 9:414\u2013424","journal-title":"Hepatobiliary Surg Nutr"},{"key":"3831_CR39","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus ocetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128. https:\/\/doi.org\/10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"key":"3831_CR40","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1080\/17425255.2021.2029405","volume":"17","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Santoni M, Mollica V et al (2021) Peripheral neuropathy and headache in cancer patients treated with immunotherapy and immuno-oncology combinations: the MOUSEION-02 study. Expert Opin Drug Metab Toxicol 17:1455\u20131466. https:\/\/doi.org\/10.1080\/17425255.2021.2029405","journal-title":"Expert Opin Drug Metab Toxicol"}],"updated-by":[{"DOI":"10.1007\/s00262-025-03999-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000}}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03831-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-024-03831-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-024-03831-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:01:19Z","timestamp":1745233279000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-024-03831-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":40,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3831"],"URL":"https:\/\/doi.org\/10.1007\/s00262-024-03831-1","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"5 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00262-025-03999-0","URL":"https:\/\/doi.org\/10.1007\/s00262-025-03999-0","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol was approved by the Institutional Review Board (IRB) and Ethics Committee (EC) of PUMCH (IRB No. JS-1391) and conformed to Good Clinical Practice guidelines and Declaration of Helsinki principles.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The informed consent was waived by the Ethics Committee (EC) of PUMCH.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"240"}}